To determine the effect of Montelukast in Asthma and Allergic rhinits patients

Montelukast is a potent and selective blocker of the CysLT1 receptor. Accordingly, a recent study has shown that Montelukast can improve symptoms of seasonal allergic rhinitis and asthma in patients with both diseases. For treatment of asthma, Montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form. Asthma and allergic rhinitis have been linked clinically for many years as "one airway one diseases". Patients with allergic asthma and rhinitis are significantly more likely to experience asthma attacks compared to patients with asthma alone. Side effects most commonly reported above placebo included headache, otitis media, upper respiratory infection, and pharyngitis

Inclusion Criteria:

• Age >18 years
• Signed Informed Consent
• Clinical diagnosis of Asthma and Allergic Rhinitis

Exclusion Criteria:

• Previous adverse reaction to Montelukast
• History of hyper-eosinophilic disorder other than atopic disease
• Female subjects who are pregnant, breast-feeding
• Any significant and active pulmonary pathology other than asthma

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor.Montelukast should be taken once daily in the evening